Pharmaceutical

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M...

BC Platforms and GeneVault partner to unlock access to large-scale real-world and genomic data from under-represented populations

Partnership expands BC Platforms' global patient catchment to include an additional 48 million patient lives across Asia, the Middle East,...

Trumps Marijuana Reclassification is Only the Beginning: Why MMJ International Holdings Takes the Lead in the Medicare and Research Reset

"Federal Marijuana Reform Is Coming-But FDA-Ready Companies Will Benefit the most" Duane Boise CEO MMJ International Holdings stated. WASHINGTON, DC...

Enhancing Signal Detection and Mitigating Placebo Response in Major Depressive Disorder Clinical Trials, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn practical signal detection approaches that reduce placebo response and improve clinician-rated outcomes in major depressive...

error: Content is protected !!